Chronic Lower Back Pain Pipeline Shows Mixed Results as Multiple Phase III Trials Report Outcomes
核心洞察
Spine BioPharma (搜索)'s SB-01 (vicatertide (搜索)) failed to meet Phase III endpoints in 417 patients with degenerative disc disease (搜索), attributed to unexpectedly strong placebo effects at certain trial sites.
Persica Pharmaceuticals (搜索)' PP353, a novel non-opioid intradiscal injection, achieved its primary endpoint in a Phase Ib trial, showing statistically significant pain reduction in 44 patients with chronic low back pain.
The chronic lower back pain (搜索) pipeline includes over 10 companies developing more than 10 treatment therapies, with emerging candidates spanning from Phase I to Phase III development stages.
The chronic lower back pain (搜索) therapeutic landscape experienced significant developments in 2025, with mixed clinical trial outcomes highlighting both the challenges and opportunities in treating this debilitating condition that affects millions of patients worldwide.
Phase III Trial Setbacks and Successes
Spine BioPharma (搜索) reported disappointing results for its lead candidate SB-01 (vicatertide (搜索)) in August 2025, as the drug failed to meet endpoints in its Phase III MODEL trial. The study enrolled 417 patients in the US with degenerative disc disease (搜索) and evaluated the TGF-β (搜索) antagonist administered via intradiscal injection. Success criteria required participants to achieve both a two-point reduction on a 10-point pain intensity NRS and a 15-point improvement on the Oswestry Disability Index (ODI). The company attributed the outcome to an unexpectedly strong placebo effect observed at certain trial sites, which may have masked the drug's efficacy.
In contrast, Persica Pharmaceuticals (搜索) announced positive Phase Ib results for PP353 in March 2025. The UK-based biotech reported that its investigational treatment, a novel non-opioid intradiscal injection, achieved the primary endpoint in trial NCT04238676. The study demonstrated a statistically significant, clinically meaningful, and durable reduction in pain among 44 patients with chronic low back pain associated with Modic type 1 changes. Following these results, the company announced plans to advance the antibiotic-based therapy into registrational studies.
Expanding Pipeline Activity
The chronic lower back pain (搜索) pipeline constitutes more than 10 key companies continuously working toward developing over 10 treatment therapies across various stages of clinical development. Emerging therapies in different phases include XTAMPZA ER (oxycodone) from Collegium Pharmaceutical (搜索), LY3016859 from Eli Lilly and Company, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot) from Camurus/Braeburn Inc., and Semdexa (SP-102) from Scilex Holding.
Mesoblast Limited (搜索) initiated patient enrollment for its Phase III clinical trial of rexlemestrocel-L in July 2024, targeting individuals with chronic low back pain resulting from inflammatory degenerative disc disease (搜索). Rexlemestrocel-L is an allogeneic, immunoselected, and commercially manufactured stromal cell therapy.
Recent Regulatory and Clinical Milestones
Scilex Holding Company announced post-hoc analysis results of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) in May 2025. The analysis assessed the clinical significance of the safety and efficacy of SP-102 (SEMDEXA™) in treating lumbosacral radicular pain, presented at the 27th Annual Meeting of the American Society of Interventional Pain Physicians.
Mainstay Medical Holdings (搜索) plc released favorable one-year primary assessment results from the RESTORE randomized clinical trial of ReActiv8 in January 2025. The data indicated that incorporating ReActiv8 Restorative Neurostimulation therapy into current standard of care leads to significantly greater improvements in back pain-related disability, pain, and overall quality of life compared to standard treatments alone.
Novel Therapeutic Approaches
Contineum Therapeutics received FDA authorization for its Investigational New Drug application for PIPE-791 in November 2024. The drug is intended for treating chronic pain related to osteoarthritis (搜索) and low back pain. PIPE-791 is a novel, brain-penetrating small molecule that acts as an antagonist to the lysophosphatidic acid 1 receptor (搜索) (LPA1R (搜索)).
The FDA also approved Tonmya (搜索) (TNX-102 SL), a sublingual form of cyclobenzaprine HCl, for treating adults with fibromyalgia (搜索) in August 2025. This represents the first new fibromyalgia drug approval in more than 15 years, providing patients with a therapeutic option specifically developed to address nonrestorative sleep and chronic pain.
Market Dynamics and Challenges
The chronic lower back pain (搜索) market faces several drivers and barriers. Rise in anti-inflammatory medications and increase in nerve cases are fueling market growth. However, high costs associated with drug development and stringent regulatory policies create obstacles in market advancement.
Key companies developing therapies include Collegium Pharmaceutical (搜索), Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited (搜索), AnGes MG Inc., Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals (搜索), DOV Pharma, Mallinckrodt, Grünenthal GmbH, and AbbVie (搜索).
Chronic lower back pain (搜索) is persistent pain in the lower spine lasting 12 weeks or longer, even after initial injury or underlying cause treatment. It may result from conditions such as degenerative disc disease (搜索), herniated discs, arthritis, spinal stenosis, or muscle strain, significantly affecting mobility, daily activities, and quality of life.